AstraZeneca

AstraZeneca will launch Palivizumab (Synagis) in October 2024 in India

GlobalData analyst consensus forecast predicts the global revenue of Pluvicto to rise from $980 million in 2023 to $4.3 billion by…

TROPION-Lung01 trial results fall short on overall survival, raising concerns for Dato-DXd's future

Biopharma sector sees market capitalisation rise to $4 trillion, driven by strong performances from Lilly, Novo Nordisk, and…

Imfinzi gains expanded use, and AstraZeneca’s shares rise after a priority review for small cell lung cancer

The investment marks a significant milestone in AstraZeneca’s growth story in India as it celebrates its 45 year in the country…

An accelerated assessment aims to speed up the European Medicines Agency’s (EMA) review of a market authorisation application

Pharmaceutical manufacturers like Boehringer Ingelheim, GSK, and AstraZeneca are participating in this initiative

Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy reduced the risk of disease progression or death by…

The trial, known as CAPItello-290, was testing whether the drug combination improved overall survival in patients